OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico

BATON ROUGE, LA--(Marketwired - June 28, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce achieving a significant milestone with the first patient in Mexico suffering from Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin (AAT) deficiency identified and scheduled to begin treatment with a leading therapy in approximately two weeks. The name of the AAT therapy is being withheld at this time for competitive reasons.

OncBioMune is utilizing Mexico's "Patient Specific" pathway, the equivalent of "Compassionate Use" in the United States, to facilitate importing the product to begin the patient's therapy immediately. AAT deficiency is a lifelong condition requiring weekly injections, with the cost of some popular insurance-covered therapies in excess of $100,000 annually.

Now that a market has been identified, OncBioMune is working to complete licensing negotiations with the treatment's manufacturer with the goal of adding the product to the Company's portfolio for the Mexican market. While utilizing the Patient Specific pathway initially, the Company will seek to leverage data used in regulatory approvals for the product in other countries, a process which management hopes to expedite through an Orphan Drug designation in Mexico, due to the rarity of the disease and lack of leading treatments.

While known to be inherited and considered one of the most common genetic disorders worldwide, no one is certain as to how many people are afflicted with AAT deficiency. Diagnosis of AAT deficiency typically only occurs post-diagnosis of lung or liver disease. A 2012 study authored by Frederick J. de Serres and Ignacio Blanco spanning nearly 100 countries estimates that 4,049 Mexicans have AAT deficiency. The Company believes an accurate estimate is a challenge due to a problem of infrequent diagnostics, leaving many adults and children unaware they have AAT deficiency and at increased risk for degenerative lung function and other maladies. Further, Mexico has a large population of immigrants from Europe, Spain in particular, where AAT deficiency is far more prevalent.

"This is absolutely a blue ocean opportunity for us that could generate tens of millions of dollars in high-margin revenue by helping just a small portion of patients with AAT deficiency in Mexico. The first patient's private insurance has already agreed to reimbursement, a positive sign for us moving forward," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Patients with AAT deficiency need to know that they have the disorder as soon as possible, information that could potentially lower the risk of developing life-threatening diseases by early intervention. We are optimistic that we will successfully negotiate the licensing agreement and fill this area of unmet medical need in Mexico."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials in 2017: a Phase 2 for early-stage prostate cancer at a major Northwest U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

OncBioMune Pharmaceuticals, prostate cancer vaccine, ProscaVax, patent, intellectual property, prostate cancer vaccine, cancer vaccines, OBMP stock, OBMP investor relations, OBMP news, OncBioMune Mexico